Xofluza
Drug
Shionogi Inc
Total Payments
$19.8M
Transactions
80,136
Doctors
37,360
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.8M | 397 | 31 |
| 2023 | $2.1M | 425 | 61 |
| 2022 | $1.6M | 5,219 | 4,094 |
| 2021 | $1.3M | 37,615 | 20,024 |
| 2020 | $1.6M | 12,473 | 8,909 |
| 2019 | $1.1M | 16,490 | 11,746 |
| 2018 | $9.2M | 7,517 | 5,378 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.5M | 2,929 | 88.7% |
| Food and Beverage | $1.2M | 76,262 | 6.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $612,691 | 406 | 3.1% |
| Travel and Lodging | $233,044 | 409 | 1.2% |
| Consulting Fee | $152,045 | 79 | 0.8% |
| Education | $2,152 | 50 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $750.00 | 1 | 0.0% |
Payments by Type
Research
$17.5M
2,929 transactions
General
$2.2M
77,207 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of S-033188 Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications CAPSTONE 2 | Shionogi Inc | $9.4M | 0 |
| Transmission Study household | Genentech, Inc. | $3.6M | 0 |
| TRANSMISSION STUDY HOUSEHOLD | Genentech, Inc. | $2.8M | 2 |
| A phase IIIB surveillance study of susceptibility to baloxavir marboxil | Genentech, Inc. | $1.0M | 1 |
| PH III STUDY OF SAFETY EFFICACY OF CAP ENDONUCLEASE IN PEDIATRIC PATIENTS | Genentech, Inc. | $299,784 | 0 |
| Ph III Study of safety efficacy of CAP Endonuclease in pediatric patients | Genentech, Inc. | $79,644 | 0 |
| BXM IN TRANSPLANT | Genentech, Inc. | $67,287 | 0 |
| Early Detection of Flu | Genentech, Inc. | $66,748 | 0 |
| The COMBO 1 Trial | Genentech, Inc. | $46,058 | 0 |
| A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza CAPSTONE 1 | Shionogi Inc | $34,012 | 0 |
| THE COMBO 1 TRIAL | Genentech, Inc. | $27,674 | 0 |
| Comparative Effectiveness of Xofluza vs Oseltamivir for Influenza Outbreak Mgmnt in US Nursing Homes | Genentech, Inc. | $27,305 | 0 |
| REDUCING INFLUENZA VIRUS TRANSMISSION THE VALUE OF ANTIVIRAL TREATMENT | F. Hoffmann-La Roche AG | $8,051 | 2 |
| Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated With Baloxavir vs Oseltamivir for Influenza: An Outpatient Prospective Survey in the United States | F. Hoffmann-La Roche AG | $6,857 | 2 |
| Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years | F. Hoffmann-La Roche AG | $5,030 | 2 |
| Ph III Study of safety efficacy of CAP Endonuclease in pediatric patients | F. Hoffmann-La Roche AG | $4,695 | 1 |
| Household Flu Transmission and Healthcare Resource Use among Patients Treated with Baloxavir versus Oseltamivir for Influenza: An Outpatient Prospective Survey in the United States | F. Hoffmann-La Roche AG | $4,525 | 2 |
| Transmission Study household | Chugai Pharmaceutical Co., Ltd. | $4,207 | 0 |
| Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study | F. Hoffmann-La Roche AG | $3,855 | 2 |
| Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated With Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey | F. Hoffmann-La Roche AG | $3,843 | 2 |
Top Doctors Receiving Payments for Xofluza
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $17.5M | 2,937 |
| , DO | Family Medicine | Pampa, TX | $75,356 | 140 |
| , D.O | Family Medicine | Brooklyn, NY | $72,122 | 118 |
| , M.D | Internal Medicine | Libertyville, IL | $62,182 | 94 |
| , D.O | Internal Medicine | Phoenix, AZ | $56,503 | 54 |
| , D.O | Family Medicine | Melbourne, FL | $54,447 | 67 |
| , MD | Pulmonary Disease | Franklin, TN | $50,855 | 50 |
| , M.D | Infectious Disease | Charlottesville, VA | $48,086 | 45 |
| , MD | Family Medicine | Harrisburg, AR | $44,924 | 8 |
| , MD | Infectious Disease | Dallas, TX | $43,343 | 46 |
| , M.D | Emergency Medicine | Brockton, MA | $43,068 | 50 |
| , M.D | Adolescent Medicine | Millburn, NJ | $37,283 | 63 |
| , M.D | Internal Medicine | West Palm Beach, FL | $28,148 | 33 |
| , M.D | General Practice | Rocky Mount, NC | $26,325 | 48 |
| , M.D | Pediatrics | Nicholasville, KY | $25,434 | 35 |
| , APRN | Family | Provo, UT | $19,174 | 32 |
| , MD | Pediatrics | Houston, TX | $16,885 | 6 |
| , MD | Geriatric Medicine | Providence, RI | $16,352 | 15 |
| , A.P.R.N | Registered Nurse | Greenville, SC | $15,875 | 25 |
| , M.D., M.S | Infectious Disease | Chicago, IL | $15,441 | 12 |
| , M.D | Family Medicine | Torrance, CA | $14,913 | 22 |
| , CRNP | Family | Haverford, PA | $14,484 | 18 |
| , CNP | Family | Cabot, AR | $13,644 | 26 |
| , M.D | Obstetrics & Gynecology | Idaho Falls, ID | $12,955 | 9 |
| , MSN, APRN, FNP-C | Family | Branford, CT | $12,550 | 20 |
Ad
Manufacturing Companies
- Shionogi Inc $9.5M
- Genentech, Inc. $8.2M
- Genentech USA, Inc. $2.0M
- F. Hoffmann-La Roche AG $111,176
- Roche Products Limited $10,470
- Chugai Pharmaceutical Co., Ltd. $4,207
- Hoffmann-La Roche Limited $76.00
Product Information
- Type Drug
- Total Payments $19.8M
- Total Doctors 37,360
- Transactions 80,136
About Xofluza
Xofluza is a drug associated with $19.8M in payments to 37,360 healthcare providers, recorded across 80,136 transactions in the CMS Open Payments database. The primary manufacturer is Shionogi Inc.
Payment data is available from 2018 to 2024. In 2024, $2.8M was paid across 397 transactions to 31 doctors.
The most common payment nature for Xofluza is "Unspecified" ($17.5M, 88.7% of total).
Xofluza is associated with 20 research studies, including "Study of S-033188 Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications CAPSTONE 2" ($9.4M).